{"id":140,"date":"2017-06-13T17:21:45","date_gmt":"2017-06-13T14:21:45","guid":{"rendered":"https:\/\/pdc-eu.com\/?page_id=140"},"modified":"2020-09-29T22:30:50","modified_gmt":"2020-09-29T19:30:50","slug":"our-focus","status":"publish","type":"page","link":"https:\/\/pdc-eu.com\/en\/bulletin\/our-focus","title":{"rendered":"Our Focus"},"content":{"rendered":"<section class=\"l-section wpb_row height_medium\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_flex valign_top type_default stacking_default\"><div class=\"vc_col-sm-12 wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_wrapper\"><div class=\"w-grid type_grid layout_180 pagination_infinite\" id=\"us_grid_1\" style=\"--gap:5rem;\" data-filterable=\"true\"><style>.layout_180 .w-grid-item-h{}.layout_180 .usg_post_date_1{color:#9e9e9e!important;font-size:0.875rem!important}.layout_180 .usg_post_taxonomy_2{color:#9e9e9e!important;font-size:0.875rem!important}.layout_180 .usg_hwrapper_1{margin-top:5px!important;margin-bottom:20px!important}<\/style><div class=\"w-grid-list\">\t<article class=\"w-grid-item size_1x1 post-138 post type-post status-publish format-standard hentry category-our-focus\" data-id=\"138\">\r\n\t\t<div class=\"w-grid-item-h\">\r\n\t\t\t\t\t\t<h2 class=\"w-post-elm post_title usg_post_title_1 entry-title color_link_inherit\"><a href=\"https:\/\/pdc-eu.com\/en\/immuno-oncology\">Immuno &#8211; oncology<\/a><\/h2><div class=\"w-hwrapper usg_hwrapper_1 pdc-list-icons align_left valign_top wrap\"><time class=\"w-post-elm post_date usg_post_date_1 has_text_color entry-date published\" datetime=\"2017-06-13T17:18:59+03:00\"><i class=\"material-icons\">access_time<\/i>June 13, 2017<\/time><\/div><div class=\"w-post-elm post_content usg_post_content_1\"><p>In the recent years, immunotherapy has become a potential strategy against various types of cancers. In light of this trend, two important components of the immune response signaling pathways &#8211; PD-1 (programmed cell death 1) and PD-L1 (programmed cell death ligand 1), are often mentioned. PD-1 is a cell membrane protein that has a role in limiting immune-induced tissue destruction at sites of active inflammation.<\/p>\n<\/div>\t\t<\/div>\r\n\t\t\t<\/article>\r\n<\/div><div class=\"w-grid-preloader\">\t<div class=\"g-preloader type_3\">\r\n\t\t<div><\/div>\r\n\t<\/div>\r\n\t<\/div>\t<div class=\"w-grid-json hidden\" onclick='return {&quot;action&quot;:&quot;us_ajax_grid&quot;,&quot;infinite_scroll&quot;:0,&quot;max_num_pages&quot;:1,&quot;pagination&quot;:&quot;infinite&quot;,&quot;template_vars&quot;:{&quot;columns&quot;:&quot;1&quot;,&quot;exclude_items&quot;:&quot;none&quot;,&quot;img_size&quot;:&quot;us_600_400_crop&quot;,&quot;ignore_items_size&quot;:0,&quot;items_layout&quot;:&quot;180&quot;,&quot;items_offset&quot;:&quot;1&quot;,&quot;load_animation&quot;:&quot;none&quot;,&quot;overriding_link&quot;:&quot;{\\&quot;url\\&quot;:\\&quot;\\&quot;}&quot;,&quot;post_id&quot;:0,&quot;query_args&quot;:{&quot;post_type&quot;:[&quot;post&quot;],&quot;tax_query&quot;:[{&quot;taxonomy&quot;:&quot;category&quot;,&quot;field&quot;:&quot;slug&quot;,&quot;terms&quot;:[&quot;our-focus&quot;]}],&quot;post_status&quot;:[&quot;publish&quot;],&quot;posts_per_page&quot;:&quot;10&quot;},&quot;orderby_query_args&quot;:{&quot;orderby&quot;:{&quot;date&quot;:&quot;DESC&quot;}},&quot;type&quot;:&quot;grid&quot;,&quot;us_grid_post_type&quot;:&quot;post&quot;,&quot;us_grid_ajax_index&quot;:1,&quot;us_grid_filter_query_string&quot;:null,&quot;us_grid_index&quot;:1,&quot;page_args&quot;:[],&quot;lang&quot;:&quot;en&quot;}}'><\/div>\r\n\t<\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"In the recent years, immunotherapy has become a potential strategy against various types of cancers. In light of this trend, two important components of the immune response signaling pathways - PD-1 (programmed cell death 1) and PD-L1 (programmed cell death ligand 1), are often mentioned. PD-1 is a cell membrane protein that has a role...","protected":false},"author":1,"featured_media":0,"parent":139,"menu_order":14,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-140","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdc-eu.com\/en\/wp-json\/wp\/v2\/pages\/140"}],"collection":[{"href":"https:\/\/pdc-eu.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdc-eu.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdc-eu.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pdc-eu.com\/en\/wp-json\/wp\/v2\/comments?post=140"}],"version-history":[{"count":0,"href":"https:\/\/pdc-eu.com\/en\/wp-json\/wp\/v2\/pages\/140\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/pdc-eu.com\/en\/wp-json\/wp\/v2\/pages\/139"}],"wp:attachment":[{"href":"https:\/\/pdc-eu.com\/en\/wp-json\/wp\/v2\/media?parent=140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}